Results 221 to 230 of about 110,182 (337)

Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.
Patrick Schummer, Caroline Glatzel, Philipp Schrüfer, Ingulf Lawrenz, Gabor Dobos, Ulrike Wehkamp, Svea Hüning, René Stranzenbach, Jan P. Nicolay, Matthias Goebeler, Marion Wobser   +10 more
wiley   +1 more source

Exploring the educational needs of patients with cutaneous lymphoma using an educational needs assessment tool. [PDF]

Front Oncol
Ivert LU, Winther AH, Jonsson P, Brauner H.   +3 more
europepmc   +1 more source

Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. [PDF]

Br J Dermatol, 2021
Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid E, Bagot M, Servitjie O, Berti E, Guenova E, Stadler R, Querfeld C, Busschots AM, Hodak E, Patsatsi A, Sanches J, Maule M, Yoo J, Kevin M, Fava P, Ribero S, Zocchi L, Rubatto M, Fierro MT, Wehkamp U, Marshalko M, Mitteldorf C, Akilov O, Ortiz-Romero P, Estrach T, Vakeva L, Enz PA, Wobser M, Bayne M, Jonak C, Rubeta M, Forbes A, Bates A, Battistella M, Amel-Kashipaz R, Vydianath B, Combalia A, Georgiou E, Hauben E, Hong EK, Jost M, Knobler R, Amitay-Laish I, Miyashiro D, Cury-Martins J, Martinez X, Muniesa C, Prag-Naveh H, Stratigos A, Nikolaou V, Quint K, Ram-Wolff C, Rieger K, Stranzenbach R, Szepesi Á, Alberti-Violetti S, Felicity E, Cerroni L, Kempf W, Whittaker S, Willemze R, Kim Y, Scarisbrick JJ.   +66 more
europepmc   +1 more source

Granuloma annulare: not as simple as it seems. [PDF]

, 2010
Parish, Lawrence Charles, Witkowski, Joseph A.   +1 more
core   +1 more source

Primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma initially demonstrating near‐complete metabolic response to BV‐CHEP

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Tristen Tze Wei Ng, Aaron James Frederiks, Jean‐Frank Iacobelli, Hun Sheng Chuah, Dejan Radeski, Thomas Anthony Delaney   +5 more
wiley   +1 more source

Significant survival disparity in Black patients with cutaneous lymphoma: a retrospective cohort study. [PDF]

Br J Dermatol
Trum NA, Chen L, Zain J, Rosen ST, Querfeld C.   +4 more
europepmc   +1 more source

From Benign Inflammatory Dermatosis to Cutaneous Lymphoma. DNA Copy Number Imbalances in Mycosis Fungoides versus Large Plaque Parapsoriasis. [PDF]

Medicina (Kaunas), 2021
Gug G, Solovan C.
europepmc   +1 more source

Cutaneous Lymphoma in a Ferret (Mustela putorius furo) [PDF]

, 1995
X. Li, Gerard B. Fox, Susan E. Erdman, D G Aspros   +3 more
openalex   +1 more source

Clinical outcomes of chlormethine gel in mycosis fungoides affecting “sensitive” areas: A retrospective case series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Gianluca Tavoletti, Gianluca Avallone, Pamela Vezzoli, Paolo Sena, Angelo V. Marzano, Emilio Berti, Silvia Alberti‐Violetti   +6 more
wiley   +1 more source

From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real‐World Evidence

European Journal of Haematology, EarlyView.
ABSTRACT B‐cell maturation antigen (BCMA)‐directed chimeric antigen receptor (CAR) T‐cell therapies have revolutionized the approach and management of relapsed/refractory multiple myeloma (RRMM), and as of 2025, idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) are the only BCMA‐targeted CAR T‐cell therapies approved by the FDA.
Hector Garcia Pleitez, Sakditad Saowapa, Andrea Ortiz Maldonado, Chanakarn Kanitthamniyom, Diego Olavarria Bernal, Lukman Tijani   +5 more
wiley   +1 more source